What is Capecitabine
Approved as Treatment by the FDACapecitabine, otherwise known as Xeloda, is approved by the FDA for 10 uses including Stage III Colon Cancer and Colorectal Carcinoma .
When to interrupt dosageThe recommended measure of Capecitabine is contingent upon the diagnosed affliction, such as Pancreatic Metastatic Cancer, Malignant Neoplasms and Esophageal Cancer. The quantity of dosage can be found in the table below, depending on the mode of delivery (e.g. Tablet or Tablet, film coated - Oral).
Capecitabine Novel Uses: Which Conditions Have a Clinical Trial Featuring Capecitabine?337 active clinical trials are investigating the potential of Capecitabine to address Duke's C Colon cancer, Pancreatic Endocrine Carcinoma and refractory Peritoneal Carcinoma.
Capecitabine Reviews: What are patients saying about Capecitabine?
Patient Q&A Section about capecitabine
What class of chemotherapy is capecitabine?
"They "trick" the cell into incorporating them into the cellular machinery in place of the normal substance.
Capecitabine is a type of chemotherapy that is called an antimetabolite. Antimetabolites are similar to normal substances within the cell. They "trick" the cell into incorporating them into the cellular machinery in place of the normal substance." - Anonymous Online Contributor
How does capecitabine fight cancer?
"Capecitabine can be used to treat breast, colon, or [rectal cancer](https://www.withpower.com/clinical-trials/rectal-cancer) by slowing or stopping the growth of cancer cells." - Anonymous Online Contributor
What are side effects of capecitabine?
"The following are potential side effects: stomach pain, loss of fingerprints, numbness, pain, tingling, or other unusual sensations in the palms of the hands or bottoms of the feet, pain, blistering, peeling, redness, or swelling of the palms of the hands or bottoms of the feet." - Anonymous Online Contributor
What is the success rate of capecitabine?
"Overall, 89% of patients taking capecitabine were still alive after 3 years, compared to 84% of patients in the control group. After 5 years, 89% of capecitabine patients were alive, compared to 83% of control patients." - Anonymous Online Contributor